<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721015</url>
  </required_header>
  <id_info>
    <org_study_id>M20-111</org_study_id>
    <secondary_id>2020-004953-57</secondary_id>
    <nct_id>NCT04721015</nct_id>
  </id_info>
  <brief_title>Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors</brief_title>
  <official_title>A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer is a condition where cells in a specific part of body grow and reproduce&#xD;
      uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which&#xD;
      cancer cells form in the tissues of the lung. The purpose of this study is to evaluate the&#xD;
      safety and efficacy (how well the study drug works against the disease) of ABBV-637 alone or&#xD;
      in combination with docetaxel/osimertinib in participants with solid tumors (NSCLC). Adverse&#xD;
      events and change in disease activity will be assessed.&#xD;
&#xD;
      ABBV-637 is an investigational drug being developed for the treatment of solid tumors. Study&#xD;
      consists of 3 parts - monotherapy dose escalation (Part 1), combination dose escalation and&#xD;
      expansion (Parts 2a and 2b) with docetaxel and combination dose escalation and expansion&#xD;
      (Parts 3a and 3b) with osimertinib. Approximately 109 adult participants with&#xD;
      relapsed/refractory (R/R) solid tumors will be enrolled in approximately 30 sites across the&#xD;
      world.&#xD;
&#xD;
      In Part 1, participants with solid tumors will receive intravenous (IV) ABBV-637 in 28-day&#xD;
      cycles. In Part 2a and 2b, participants will receive IV ABBV-637 in combination with IV&#xD;
      docetaxel in 28-day cycles. In Part 3a and 3b, participants will receive intravenous (IV)&#xD;
      ABBV-637 in combination with daily oral tablets of osimertinib in 28 days cycle.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. Treatment effects will be monitored by medical assessments, blood tests, side effect&#xD;
      reporting, and questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">November 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Objective Response Rate (ORR) (Part 2 &amp; 3)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>ORR is defined as the percentage of participants with a confirmed response (CR) or partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response Rate (ORR) (Part 1)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>ORR is defined as the percentage of participants with a confirmed response (CR) or partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) for ABBV-637 Administered as Monotherapy (Part 1)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>DOR is defined as the time from the initial response of CR/PR per investigator review according to RECIST version 1.1 criteria to the first occurrence of radiographic disease progression, clinical progression or death from any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) for ABBV-637 in Combination With Docetaxel (Part 2 &amp; 3)</measure>
    <time_frame>Up to approximately 20 months</time_frame>
    <description>DOR is defined as the time from the initial response of CR/PR per investigator review according to RECIST version 1.1 criteria to the first occurrence of radiographic disease progression, clinical progression or death from any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) for ABBV-637 in Combination With Docetaxel (Part 2 &amp; 3)</measure>
    <time_frame>Up to approximately 20 months</time_frame>
    <description>PFS is defined as the time from the first dose of any study drug to a documented radiographic disease progression according to RECIST version 1.1 as determined by the investigator, clinical progression or death from any cause, whichever occurs earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for ABBV-637 in Combination With Docetaxel (Part 2 &amp; 3)</measure>
    <time_frame>Up to approximately 12 months after last dose of study drug</time_frame>
    <description>OS is defined as the time from the first dose of any study drug until death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Advanced Solid Tumors Cancer</condition>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Part 1: ABBV-637 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of ABBV-637 in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2a: ABBV-637 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of ABBV-637 in combination with docetaxel in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2b: ABBV-637 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-637 at dose determined in Part 2a in combination with docetaxel in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3a: ABBV-637 + Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of ABBV-637 in combination with osimertinib in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3b: ABBV-637 + Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-637 at dose determined in Part 3a in combination with osimertinib in 28-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-637</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Part 1: ABBV-637 Monotherapy</arm_group_label>
    <arm_group_label>Part 2a: ABBV-637 + Docetaxel</arm_group_label>
    <arm_group_label>Part 2b: ABBV-637 + Docetaxel</arm_group_label>
    <arm_group_label>Part 3a: ABBV-637 + Osimertinib</arm_group_label>
    <arm_group_label>Part 3b: ABBV-637 + Osimertinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Part 2a: ABBV-637 + Docetaxel</arm_group_label>
    <arm_group_label>Part 2b: ABBV-637 + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Oral Tablets</description>
    <arm_group_label>Part 3a: ABBV-637 + Osimertinib</arm_group_label>
    <arm_group_label>Part 3b: ABBV-637 + Osimertinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic solid tumor diagnosis (Part 1).&#xD;
&#xD;
          -  Participants enrolled in Part 2 and Part 3(combination dose escalation and expansion)&#xD;
             must have non-small cell lung cancer (NSCLC) epidermal growth factor receptor&#xD;
             (EGFR)-expressing per central laboratory testing.&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  For Part 1 only - history of relapsed/refractory (R/R) disease that has progressed on&#xD;
             all standard of care therapy.&#xD;
&#xD;
          -  For Part 2 only - history of RR NSCLC that has progressed after treatment with&#xD;
             platinum-based chemotherapy regimen and either immune checkpoint inhibitor or targeted&#xD;
             therapy and may not have been treated with prior single agent chemotherapy.&#xD;
&#xD;
          -  For Part 3 only - history of RR NSCLC that has progressed on osimertinib&#xD;
&#xD;
          -  Meet the laboratory values as described in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History (within 6 months) of congestive heart failure (defined as New York Heart&#xD;
             Association, Class 2 or higher), ischemic cardiovascular event, cardiac arrhythmia&#xD;
             requiring pharmacological or surgical intervention, pericardial effusion, or&#xD;
             pericarditis.&#xD;
&#xD;
          -  Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except&#xD;
             alopecia.&#xD;
&#xD;
          -  For Part 3 only: History of interstitial lung disease (ILD) or pneumonitis that&#xD;
             required treatment with systemic steroids, nor any evidence of active ILD or&#xD;
             pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 231209</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 225698</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute /ID# 225358</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute at Rhode Island Hospital /ID# 226145</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903-4923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics /ID# 225359</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists - Fairfax /ID# 225693</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital /ID# 228350</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Health /ID# 225638</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hopital de la Timone /ID# 225779</name>
      <address>
        <city>Marseille CEDEX 05</city>
        <state>Bouches-du-Rhone</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie /ID# 225778</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie /ID# 225829</name>
      <address>
        <city>Paris CEDEX 05</city>
        <state>Ile-de-France</state>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy /ID# 226624</name>
      <address>
        <city>Villejuif Cedex</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Georges Fran√ßois Leclerc /ID# 226760</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud /ID# 225780</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 225585</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 225586</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 225725</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital /ID# 225724</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center /ID# 231887</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggido</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System Severance Hospital /ID# 233774</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 231886</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center /ID# 231888</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro, Majadahonda /ID# 226096</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron /ID# 225976</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz /ID# 225975</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre /ID# 225977</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria /ID# 225978</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital /ID# 225944</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Ho /ID# 225946</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors Cancer</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Cancer</keyword>
  <keyword>ABBV-637</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Osimertinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

